S 2336 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Halting the Epidemic of Addiction and Loss Act of 2025
To ensure references to opioid overdose reversal agents in certain grant programs of the Department of Health and Human Services are not limited to naloxone.
Summary
This bill directs the Department of Health and Human Services to broaden references to opioid overdose reversal medications in federal grant programs. Currently, many HHS regulations and guidance documents specifically mention naloxone when discussing opioid overdose treatment. The bill requires HHS to update these references within one year to include any opioid overdose reversal drug that has been approved by the Food and Drug Administration, not just naloxone. The changes apply to grant programs addressing opioid misuse, including State and Tribal Opioid Response Grants and substance use disorder prevention programs.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Sen. Cornyn, John [R-TX] (R-TX)
1 cosponsor
Money behind the sponsor
Top reported contributors to John Cornyn’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- CAPITAL GROUP $22,500
- ANDREESSEN HOROWITZ $16,500
- PALANTIR TECHNOLOGIES $13,686
- WINKLEVOSS CAPITAL MANAGEMENT $13,200
- BLACKSTONE $12,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for John Cornyn → · Outside spending →
Actions (2)
- Jul 17, 2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. · senate
- Jul 17, 2025 Introduced in Senate
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE SENATE OF THE UNITED STATES
July 17, 2025
Mr. Cornyn (for himself and Ms. Hassan) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions
A BILL
To ensure references to opioid overdose reversal agents in certain grant programs of the Department of Health and Human Services are not limited to naloxone.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Halting the Epidemic of Addiction and Loss Act of 2025”.
SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL AGENTS IN HHS GRANT PROGRAMS.
(a) In General.—The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for emergency treatment of a known or suspected opioid overdose.
(b) Existing References.—
(1) Update.—Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall update all references described in paragraph (2) to be inclusive of any opioid overdose reversal drug that has been approved or otherwise authorized for use by the Food and Drug Administration.
(2) References.—A reference described in this paragraph is any reference to an opioid overdose reversal drug (such as naloxone) in any regulation or guidance of the Department of Health and Human Services that—
(A) was issued before the date of enactment of this Act; and
(B) is included in—
(i) the grant program for State and Tribal response to opioid use disorders under section 1003 of the 21st Century Cures Act (42 U.S.C. 290ee-3a) (commonly referred to as “State Opioid Response Grants” and “Tribal Opioid Response Grants”); or
(ii) the grant program for priority substance use disorder prevention needs of regional and national significance under section 516 of the Public Health Service Act (42 U.S.C. 290bb-22). <all>
Comments